Efficacy of lurasidone on anxiety symptoms in patients with schizophrenia: A pooled post hoc analysis of five randomized, placebo-controlled trials.

ABSTRACT:

Aim

Comorbid anxiety disorders and their symptoms are common in schizophrenia and may occur before a relapse. The aim of this post hoc analysis is to investigate the efficacy of lurasidone on comorbid anxiety symptoms in patients with schizophrenia.

Methods

Data were pooled from five Phase 3 randomized, double-blind, placebo-controlled 6-week trials of lurasidone treatment of schizophrenia, focusing on the 40 and 80 mg doses compared with placebo. Subgroup analyses were performed in two subgroups: severe (baseline Positive and Negative Syndrome Scale [PANSS] G2 anxiety score ≥ 4) and non-severe anxiety (baseline PANSS G2 score < 4).

Results

In the severe anxiety group, both the 40 and 80 mg doses of lurasidone significantly reduced PANSS G2 score from Weeks 2 to 6 com

SUBMITTER: Nemoto T 

PROVIDER: S-EPMC12626723 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature